Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 More on subgroup analyses in clinical trials.

Literature DB >> 18463389

Review 1. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors: David M Kent; Ewout Steyerberg; David van Klaveren
Journal: BMJ Date: 2018-12-10

Review 2. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors: Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal: Nat Rev Drug Discov Date: 2011-07-01 Impact factor: 84.694

3. Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions.

Authors: David van Klaveren; Yvonne Vergouwe; Vasim Farooq; Patrick W Serruys; Ewout W Steyerberg
Journal: J Clin Epidemiol Date: 2015-02-27 Impact factor: 6.437

4. Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument.

Authors: David M Kent; Robin Ruthazer; Carole Decker; Philip G Jones; Jeffrey L Saver; Erich Bluhmki; John A Spertus
Journal: Neurology Date: 2015-08-19 Impact factor: 9.910

5. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.

Authors: Ann A Lazar; Bernard F Cole; Marco Bonetti; Richard D Gelber
Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544

6. Improving Patient Care Using the Johnson-Neyman Analysis of Heterogeneity of Treatment Effects According to Individuals' Baseline Characteristics.

Authors: Ann A Lazar; Stuart A Gansky; Donald D Halstead; Anthony Slajs; Jane A Weintraub
Journal: J Dent Oral Craniofac Epidemiol Date: 2013-10-01

7. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.

Authors: Issa J Dahabreh; Rodney Hayward; David M Kent
Journal: Int J Epidemiol Date: 2016-12-01 Impact factor: 7.196

8. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.

Authors: Ajar Kochar; Anne S Hellkamp; Yuliya Lokhnygina; W Schuyler Jones; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Jonathan P Piccini; Manesh R Patel
Journal: Clin Cardiol Date: 2018-02-01 Impact factor: 2.882

9. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Authors: Meredith M Regan; Prudence A Francis; Olivia Pagani; Gini F Fleming; Barbara A Walley; Giuseppe Viale; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Graziella Pinotti; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544

10. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.

Authors: Ann A Lazar; Marco Bonetti; Bernard F Cole; Wai-Ki Yip; Richard D Gelber
Journal: Clin Trials Date: 2015-10-22 Impact factor: 2.486